Whalesbook
📉 The Financial Deep Dive
The Numbers: Piramal Pharma Limited presented a Q3 FY26 with a significant divergence between its standalone and consolidated performance. Standalone revenue from operations fell 4.20% YoY to ₹1,195.81 Cr. However, standalone Profit Before Tax (PBT) rose 14.09% YoY to ₹181.87 Cr before an exceptional item of ₹26.94 Cr related to New Labour Codes, resulting in a post-exceptional PBT of ₹154.93 Cr (down 2.81% YoY). Standalone Net Profit After Tax (PAT) grew by a healthy 8.51% YoY to ₹128.91 Cr, with Basic EPS at ₹0.97 (up 7.78% YoY). For the nine months ended December 31, 2025 (9M FY26), standalone revenue decreased 8.42% YoY to ₹3,292.95 Cr, while PAT increased 5.86% YoY to ₹438.38 Cr.
In stark contrast, consolidated revenue for Q3 FY26 decreased by 2.92% YoY to ₹2,139.87 Cr. The company reported a substantial net loss of ₹136.19 Cr for the quarter, a sharp turnaround from a net profit of ₹3.68 Cr in the prior year's period. This resulted in a Basic EPS of -₹1.03. The consolidated net loss for 9M FY26 widened significantly to ₹317.11 Cr from ₹62.37 Cr in 9M FY25.
The Quality: The consolidated results were significantly impacted by exceptional items totalling ₹41.11 Cr in Q3 FY26. These included ₹26.94 Cr for the impact of new Labour Codes and a one-time settlement of £1,250,000 (₹14.60 Cr) by its UK subsidiary. The shift from a consolidated profit to a substantial loss underscores operational or financial challenges within the group's broader structure, despite the standalone entity's profitability. The lack of explicit margin figures makes direct comparative analysis difficult, but the net loss is the primary indicator of deteriorating consolidated profitability.
The Grill: The financial results announcement did not include any specific forward-looking guidance from the management or commentary on the outlook. This absence leaves investors without a clear indication of management's expectations for future performance or strategic direction beyond the announced acquisition.
🚩 Risks & Outlook
The company's immediate outlook is shadowed by the consolidated net loss and declining revenues. Key risks include the successful integration and financial performance of the newly announced acquisition of Kenalog® from Bristol-Myers Squibb. The deal involves an upfront payment of USD 35 million (₹314.58 Cr) and contingent consideration up to USD 65 million (₹584.22 Cr), which represents a significant financial commitment. Investors will be watching closely for how this acquisition impacts future earnings, debt levels, and market positioning. The ongoing challenges highlighted by the consolidated results suggest potential headwinds in operational efficiency or market competitiveness that need to be addressed. The lack of forward guidance further amplifies uncertainty.